PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c - PACE-CME

PCSK siRNA on top of maximally tolerated statin therapy potently lowers LDLc

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
AHA 2019
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
- Prof. Freek Verheugt, MD
Fish oil treatment reduces several plaque parameters after 9 months
Fish oil treatment reduces several plaque parameters after 9 months
AHA 2019
Fish oil treatment reduces several plaque parameters after 9 months
- Prof. Lawrence Leiter, MD
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
AHA 2019
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
- Prof. Donald Lloyd-Jones